🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7 results for “secukinumab” Clear

  1. PREDNISONE, Placebo to AIN457 150mg/1mL solution for injection in pre-filled syringe, SECUKINUMAB, PREDNISONE, Placebo to Prednisone 1 mg, 2.5mg, 5mg, 20mg hard gelatin capsule with tablet content, PREDNISONE, PREDNISONE, SECUKINUMAB, Placebo to AIN457 300mg/2mL solution for injection in pre-filled syringe

    Novartis Ophthalmics Europe

    Giant cell arteritis (GCA)

    phase 3 small molecule active

    1 trial

  2. Placebo to AIN457 300mg/2mL Solution for injection in pre-filled syringe, SECUKINUMAB

    Novartis Ophthalmics Europe

    Hidradenitis suppurativa

    phase 3 small molecule active

    1 trial

  3. SECUKINUMAB

    Novartis Ophthalmics Europe

    Polymyalgia Rheumatica

    phase 3 small molecule active

    1 trial

  4. TOCILIZUMAB , SECUKINUMAB , ANAKINRA , ADALIMUMAB , RITUXIMAB, USTEKINUMAB

    Pari Pharma GmbH

    Patients displaying a non-classified, severe and resistant inflammatory disease

    phase 2 small molecule active

    1 trial

  5. Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR

    Novartis Ophthalmics Europe

    Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA)

    phase 1 other active

    1 trial

  6. Placebo to AIN457 150 mg/1 mL Solution for injection in pre-filled syringe, SECUKINUMAB

    Novartis Ophthalmics Europe

    non-radiographic axial spondyloarthritis

    approved small molecule active

    1 trial

  7. Secukinumab 300 MG; Tofacitinib 11mg

    First Tracks Biotherapeutics

    Hidradenitis Suppurativa

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources